psoriasis were as follows: 13% were currently taking a biologic, 42% would consider taking a biologic, 17% had previously taken a biologic, and 24% would not consider taking a biologic. Hierarchical and non-hierarchical cluster analyses were applied to the moment-to-moment affect traces that identified four unique patient clusters (# 1-4). MDA was used to identify the five most impactful time periods within the focus group audio segments. Cluster composition profiles were identified based upon demographic information and patient responses to behavioral and attitudinal questions. CONCLUSIONS: Understanding complex patient perspectives on coping with disease is essential for delivering appropriate treatments over the lifelong course of psoriasis. This novel methodology begins to bridge this knowledge gap in understanding the patient-centered view of psoriasis. Furthermore, it improves the likelihood of recommending treatments in alignment with the patient's needs to improve health-related quality-of-life, productivity, and well-being.
OBJECTIVES:
To elicit modal salient behavioral beliefs, normative referents and control beliefs of pharmacists regarding their intention to utilize online accessible prescription drug monitoring program (PDMP) data when the validity of the prescription or patient need is in question. METHODS: One hour focus groups were conducted with a convenience sample of central Texas community pharmacists with varied backgrounds and experiences. The theory of planned behavior was used as the theoretical framework for the focus group guide, which consisted of nine open-ended questions to capture PDMP advantages/disadvantages, important influencers of utilization, and perceived facilitators or barriers. Content analysis was performed on participants' written responses to questions and focus groups' transcripts. RESULTS: Three focus groups (Total N ϭ 23) were conducted. Nine behavioral beliefs, eight normative referents and eight control beliefs were identified from the focus groups. Regarding advantages/disadvantages, pharmacists most frequently mentioned that PDMP utilization would ensure appropriate controlled medication therapy and prevent diversion. However, pharmacists were fearful of potential increased liability as a result of having access to patients' controlled medication data. Important individuals or groups that pharmacists identified as influential to their decision to utilize PDMP data were regulatory agencies (e.g., board of pharmacy), prescribers and pharmacy employers. The most important belief that would facilitate PDMP utilization was interfacing the PDMP database with their existing pharmacy software. The most frequently mentioned barrier was lack of time to access data. CONCLUSIONS: The identification of items that may influence pharmacists' utilization of PDMP data when dispensing controlled medications may be helpful to PDMP administrators' implementation of online accessible PDMPs. Increased utilization of PDMPs by pharmacists may lead to a decrease in morbidity and mortality associated with controlled medication therapy.
PSY48 BUTRANS® REMS HEALTH CARE PROVIDER TRAINING GUIDE RECALL TESTING
Coplan P, Kadakia A, Downing J, Kline A, Sessler N Purdue Pharma L.P., Stamford, CT, USA OBJECTIVES: Purdue implemented a Risk Evaluation and Mitigation Strategy (REMS) for Butrans (buprenorphine) Transdermal System that included distribution of a printed REMS Training in December 2010 to prescribers of extended release/long acting opioids to inform them on the risks and safe use of Butrans. Prescribers who completed the training were asked to return a signed form with a short post-test evaluation attached. We report on the results of the post-test evaluation by prescribers who completed the training between December 2010 and February 2011. METHODS: The training guide was distributed to prescribers via paper mail and field sales force in December 2010. The educational confirmation form included 7 multiple choice questions with 26 response items measuring understanding of appropriate indication, dosing strength, storage and the risk factors and signs of overdose, abuse and misuse. A multiple linear regression model was computed to determine the mean total score and factors affecting it. RESULTS: A total of 502 prescribers returned the form which included 36% general practitioners and 64% specialists. The average score for correctly answering all the items was 97%. Average total score did not vary between general practitioners and specialists. Prescribers scored relatively lower on items that individuals with a family history of substance abuse are at increased risk of opioid abuse (82%) and individuals with mental illness are at increased risk for opioid abuse (76%). CONCLUSIONS: Prescribers completing the REMS training had high levels of understanding of the core messages of the Butrans REMS; however, lower knowledge levels that mental illness and family history increase the risk of opioid abuse were identified. Another survey of a random sample of Butrans prescribers from around the United States is in progress.
PSY49 SMOKING CESSATION MEDICATION USE AMONG ADULT SMOKERS WITH VARIOUS BODY WEIGHT LEVELS -AN NHANES STUDY
Abughosh S, Yu Y, Yang M, Rajan SS, Essien EJ University of Houston, Houston, TX, USA OBJECTIVES: Recent evidence suggests a higher risk of diabetes following smoking cessation possibly related to the expected weight gain. Quitting smoking, however, remains recommended. The objective was to examine differences of smoking cessation medication prescribing among smokers with different body weight levels using the Health and Nutritional Examination Survey (NHANES) data. METHODS: A retrospective cross-sectional study was conducted using the NHANES data from 1999 to 2008. The study included adults aged Ն 18 years who self-reported currently using tobacco. The outcome variable was receiving a cessation medication (Bupropion or Varenicline) vs. not. The independent variables included body mass index (BMI), gender, age, race, education, marital status, family income, insurance type, poverty income ratio (PIR), and health status. Multivariate logistic regression analyses were conducted to assess the association between the main independent variable (BMI) as well as socio-demographic and general health status characteristics with the outcome variable. RESULTS: A total of 7743 adult smokers were included. Among normal weight smokers, 2.72% were prescribed cessation medication, while 1.57% and 2.54% among overweight and obese smokers were prescribed cessation medication, respectively. Logistic regression results showed that smokers who were overweight were less likely to be prescribed cessation medications than those with normal weight (OR: 0.441, 95% CI: 0.212-0.915). Male smokers, white race, having government insurance, college degree or above, PIR above average, were significant factors of receiving a cessation medication. CONCLUSIONS: The study documented a lower rate of smoking cessation medication use among overweight smokers compared to normal weight smokers. Whether this finding is related to physician or patient preferences remains uncertain. Future studies should investigate the reasons for this discrepancy and develop effective interventions to aid overweight smokers in quitting.
PSY50 SMOKING CESSATION MEDICATION UTILIZATION PATTERN AMONG ADULT SMOKERS WITH DIFFERENT BODY WEIGHT LEVELS -A NAMCS STUDY
obese class III (OR: 0.399, 95% CI: 0.228 -0.698) smokers were less likely to be prescribed cessation medications compared to those with normal weight. The weight spline had a significant decrease in the interval of overweight (OR: 0.853, 95% CI: 0.729-0.999). Male smokers, aged Յ 65 years, white race, having private insurance, having depression, cardiovascular diseases diagnosis, and tobacco counseling, were significant predictors of having a smoking cessation prescription. CONCLUSIONS: Overweight or obese smokers were less likely to be prescribed cessation medications. Future research is needed to investigate the reasons behind this difference and develop interventions to help overweight and obese smokers quit.
PSY51

USE OF NARCOTIC MEDICATIONS AMONG A LARGE COMMERCIALLY-INSURED POPULATION IN THE UNITED STATES
Tian Y, Henderson RR, Frazee SG Express Scripts, Inc., St. Louis, MO, USA OBJECTIVES: Narcotic medications are increasingly becoming the most-abused medicines in the United States, accounting for hundreds of deaths and thousands of emergency room visits. The objective of this study is to examine the use of narcotic medications in a commercially insured population. METHODS: Retrospective pharmacy claims from a large US pharmacy benefit manager between January 2010 to December 2010 examined the prevalence, utilization and cost trend of narcotic medications (GPI2ϭ65). Only commercially insured patients with integrated and funded prescription benefits were included in the analysis. RESULTS: While females filled more narcotic prescriptions than males, male patients used more expensive narcotic medications than their female counterparts ($58 per script and $45 per script, respectively). The largest difference in cost per prescription between males and females was in the 25-34 age groups ($64 per script and $33 per script for male and female, respectively). Within this age group, males spent 42% of their overall narcotic cost on Suboxone® and 16% on Oxycontin®, whereas females only spent 21% on Suboxone®, 15% on hydrocodone-acetaminophen, and 14% on Oxycontin®. Males had lower generic fill rate (GFR) compared to their female counterparts (86% and 95%, respectively). Consequently, the Per Member per Year (PMPY) narcotic cost for males was $13.04 higher than females 24-35 years of age. As patient age increases, however, the trend is reversed: female PMPY narcotic cost is $19.35 higher than male counterparts aged 75 or older. The utilization and cost of narcotic medications differ by geographic region with Oklahoma, Nevada, Utah, Ohio, and Alabama ranked as the Top 5 most costly and Alabama, Oklahoma, Tennessee, Mississippi, and Wyoming having the highest utilization. CONCLUSIONS: Results from this analysis can provide insights into the utilization and cost of narcotic medications.
PSY52 IS ANTI-OBESITY MEDICATION (AOM) USE MEDICALLY OR SOCIALLY DRIVEN? AN ANALYSIS OF PREDICTORS OF AOM USE AMONG OVERWEIGHT AND OBESE FEMALE MEPS RESPONDENTS
Alipoe A 1 , Hong SH 2 1 University of Tennessee Health Science Center, Memphis, TN, USA, 2 University of Tennessee, Memphis, TN, USA OBJECTIVES: Currently, little is known about anti-obesity medication (AOM) utilization. The purpose of this research was to explore predictors of utilization among overweight and obese females within the MEPS database and to determine whether use is primarily socially or medically driven. METHODS: A retrospective case-control study design using 2003-2008 data from the Medical Expenditure Panel Survey (MEPS) was performed. Datasets were generated by linking Full-Year Consolidated Files to Prescribed Medicine Files in MEPS for each year. The Conditions Files for each year were linked to ascertain whether or not respondents possessed a comorbidity of interest (diabetes, hyperlipidemia, hypertension). The Multum Lexicon File, released in Fall 2003, was used to identify AOM users in MEPS. Logistic regression analysis was used to indicate whether obese/overweight respondents take an AOM in that year, controlling for indicated Љmedically necessaryЉ or Љsocially desirableЉ related variables, and other potentially significant variables. Proc means and proc freq in SAS 9.1 were used to generate descriptive statistics. RESULTS: LR results show that women who are above the age of 35 are significantly less likely to consume anti-obesity medications (Ages 36-49, ORϭ0.570, pϭ0.0082; Ages 50-64, ORϭ0.366, pϽ0.001); oldest females are least likely to consume them (Ages 65ϩ, ORϭ0.072, pϽ0.001). Married females are significantly more likely to consume anti-obesity medications (ORϭ1.695, pϭ0.003). With unit increases in BMI, females are 1.03 (p Ͻ0.001) more likely to take anti-obesity medications. Other significant variables included education and possession of private insurance. Dummy variables representing comorbidities were not significant predictors of AOM use. CONCLUSIONS: Consumption of anti-obesity medications may be more socially-rather than medically-driven, with more socially-related variables appearing significant in the model. Increased monitoring patients who receive these medications is of urgent importance. AOM use potentially involves adverse effects; physicians' role in prescribing these potentially dangerous medications may need to be addressed.
PSY53
EVALUATION OF DAILY AVERAGE CONSUMPTION (DACON) OF OXYCODONE CR AND OXYMORPHONE ER USING AN INTERRUPTED TIME SERIES ANALYSIS
Puenpatom RA 1 , Szeinbach SL 2 , Ma L 1 , Ben-joseph R 1 , Summers KH 1 1 Endo Pharmaceuticals, Inc., Chadds Ford, PA, USA, 2 Ohio State University, Columbus, OH, USA OBJECTIVES: Oxycodone controlled-release (CR) and oxymorphone extended-release (ER) are commonly prescribed, long-acting opioids, approved for twice-daily dosing. We compared Daily Average Consumption (DACON) for oxycodone CR and oxymorphone ER before and after the introduction of reformulated oxycodone CR. METHODS: This was a retrospective claims database analysis using pharmacy claims from the MarketScan® database during January 2010 through March 2011. The Interrupted time series analysis was used to evaluate the impact of the introduction of reformulated oxycodone CR on DACON of both drugs. RESULTS: Before the introduction of reformulated oxycodone CR, the mean DACON for oxycodone CR was higher than the mean DACON for oxymorphone ER in both highest and all lower strengths pairs by 0.51 and 0.46 tablets, respectively. After the introduction, the difference in mean DACON between the two drugs became 0.45 tablets for the highest and 0.40 tablets for the lower strengths. Interrupted time series results demonstrated that the immediate and overall impact on DACON of the reformulated oxycodone CR was minimal, while there were no changes in the DACON for oxymorphone ER as a result of the introduction. The estimated difference in average DACON for oxycodone CR decreased by 0.1 tablets or 3.7% (P Ͻ 0.001) 6 months after the new formulation was introduced. CONCLUSIONS: Mean DACON was higher for oxycodone CR compared to oxymorphone ER by 0.4 tablets per day for all dosage strengths for the entire study period. After the introduction of reformulated oxycodone CR, the DACON for oxycodone CR was slightly mitigated; however, there was a minimal impact on the mean difference between oxycodone CR and oxymorphone ER. Estimated coefficients were considered significant when pϽ0.05. RESULTS: In all countries the rate increased with the age. Mexico had the lower rates, which remain nearly constant over the years (0.09/100,000 inhabitants, pϭ NS). In Chile, the rate has increased over the years (␤ϭ0.45; annual risk ratio: 1.568 pϽ0.001), different from Brazil that showed a decrease (␤ϭ-0111; annual risk ratioϭ0.893; pϽ0.001). CONCLUSIONS: Reports from reference centers showed an increase in the number of cases in the three countries; however in Mexico the number of patients still very low. Therefore, the trend of hospital admission rates in Chile and Mexico seem to be similar as the reported disease frequency. Regarding Brazil, a possible explanation for the decrease in hospital admission could be changes in treatment practices, the financing of biological therapies in Public Health System since 2002. The trends of hospital admission vary across the Latin America countries, and national assistance programs for CD seem to have an impact on hospital admission rate.
PSY55 ENTRY AND ACCESS EXPECTATION FOR BIOSIMILARS IN THE UNITED STATES
Schwartz EL 1 , Gould AJ 2 1 PriceSpective LLC, San Diego, CA, USA, 2 PriceSpective LLC, El Segundo , CA, USA OBJECTIVES: The objective of this research was to conduct primary research with US managed care decision-makers to understand their perceptions and management expectations for pending biosimilar market availability in the United States. METHODS: Explorative primary research (nϭ20) was conducted with a sample of Managed Care Organization (MCO) decision-makers composed of pharmacy and medical directors, clinical pharmacists, and field experts involved in evaluating expectations of biosimilar management. Interviews were conducted from January to March 2011 and consisted of individual one-hour phone cponversations. Survey development focused on addressing how biosimilar evaluations for plan coverage will be made and vary by therapeutic class including testing of: Erythropoietinstimulating agents (ESA), cancer monoclonal antibodies (mAb), anti-tumor necrosis factor agents (anti-TNF), and granulocyte-colony stimulating factors (G-CSF). Baseline knowledge that US payers had about biosimilars and abbreviated pathway development was also tested. Qualitative survey methods for eliciting stated preferences were used. RESULTS: Payers recognize differences between biosimilars and small molecule generics in molecular structure and manufacturing processes; however, uncertainty exists around exact payer definitions for biosimilarity. Payers view biosimilars as alternative branded products rather than small molecule generics. Research also indicated that contrary to review for small molecule generics, formulary review for biosimilar products will likely vary by class since different drugs and indications may require different evidence. Specifically, variance in biosimilar management decisions will vary depending on the sensitivity level to manage the category. Payers expect biosimilar cost offsets within the range of 11-30% from innovator brands. CONCLUSIONS: Presently, discussions about biosimilar formulary review have been informal and high-levelt. Biosimilar product value assessments will differ from the case of small molecule generics and coverage policies will vary by class. Budgetary and economic impact is the major driver in proposed utilization management controls, but will need to be balanced in light of product comparisons in safety and efficacy.
